Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1067-1075

  Santoro, Ana B ^a   Vargens, Daniela D ^a   De Camargo Barros Filho, Mateus ^b   Bulzico, Daniel A ^a   Kowalski, Luiz Paulo ^b   Meirelles, Ricardo M R ^c   Paula, Daniela P ^d   Neves, Ronaldo R S ^c   Pessoa, Cencita N ^a   Struchine, Claudio J ^e   Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^d FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^e INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Brazilian population; Differentiated thyroid cancer; Iodothyronine deiodinases; L thyroxine; Pharmacogenomics; Uridine glucuronyltransferases

Indexed keywords

DIO1 PROTEIN; DIO2 PROTEIN; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; IODINE 131; LEVOTHYROXINE; PROTEIN DERIVATIVE; THYROTROPIN; THYROXINE DEIODINASE; UNCLASSIFIED DRUG; GLUCURONOSYLTRANSFERASE; IODIDE PEROXIDASE; IODOTHYRONINE DEIODINASE TYPE I; IODOTHYRONINE DEIODINASE TYPE II; THYROXINE; UDP-GLUCURONOSYLTRANSFERASE, UGT1A3; UGT1A1 ENZYME;

ADULT; ARTICLE; BODY WEIGHT; DIFFERENTIATED THYROID CANCER; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GLUCURONIDATION; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; ADENOCARCINOMA, FOLLICULAR; ANTAGONISTS AND INHIBITORS; BLOOD; CARCINOMA; CLINICAL TRIAL; COHORT ANALYSIS; DOSE RESPONSE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; REGRESSION ANALYSIS; THYROID NEOPLASMS;

ADENOCARCINOMA, FOLLICULAR; ADULT; CARCINOMA; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; IODIDE PEROXIDASE; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 84919339785     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12437     Document Type: Article

References (33)

1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-214.
2. Pacini F, Castagna MG, Brilli L, Pentheroudakis G, ESMO Guidelines Working Group. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl. 7): vii110-9.
3. Panicker V. Genetics of thyroid function and disease. Clin Biochem Rev 2011; 32: 165-75.
4. Maia AL, Goemann IM, Meyer EL, Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol 2011; 209: 283-97.
5. Arrojo E, Drigo R, Fonseca TL, Werneck-de-Castro JP, Bianco AC. Role of the type 2 iodothyronine deiodinase (D2) in the control of thyroid hormone signaling. Biochim Biophys Acta 2013; 1830: 3956-64.
6. Findlay KA, Kaptein E, Visser TJ, Burchell B. Characterization of the uridine diphosphate-glucuronosyltransferase-catalyzing thyroid hormone glucuronidation in man. J Clin Endocrinol Metab 2000; 85: 2879-83.
7. Yoder Graber AL, Ramírez J, Innocenti F, Ratain MJ. UGT1A1 28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics 2007; 17: 619-27.
8. Tong Z, Li H, Goljer I, McConnell O, Chandrasekaran A. In vitro glucuronidation of thyroxine and triiodothyronine by liver microsomes and recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2007; 35: 2203-10.
9. Yamanaka H, Nakajima M, Katoh M, Yokoi T. Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 2007; 35: 1642-8.
10. Kato Y, Ikushiro S, Emi Y, Tamaki S, Suzuki H, Sakaki T, Yamada S, Degawa M. Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab Dispos 2008; 36: 51-5.
11. Vargens DD, Neves RR, Bulzico DA, Ojopi EB, Meirelles RM, Pessoa CN, Prado CM, Gonçalves PA, Leal VL, Suarez-Kurtz G. Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer. Pharmacogenet Genomics 2011; 21: 341-3.
12. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95: 8170-4.
13. Riedmaier S, Klein K, Hofmann U, Keskitalo JE, Neuvonen PJ, Schwab M, Niemi M, Zanger UM. UDP-glucuronosyltransferase (UGT) polymorphisms affect atorvastatin lactonization in vitro and in vivo. Clin Pharmacol Ther 2010; 87: 65-73.
14. Cho SK, Oh ES, Park K, Park MS, Chung JY. The UGT1A3 2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genomics 2012; 22: 598-605.
15. Peeters RP, van den Beld AW, Attalki H, Toor H, de Rijke YB, Kuiper GG, Lamberts SW, Janssen JA, Uitterlinden AG, Visser TJ. A new polymorphism in the type II deiodinase gene is associated with circulating thyroid hormone parameters. Am J Physiol Endocrinol Metab 2005; 289: E75-81.
16. Mentuccia D, Proietti-Pannunzi L, Tanner K, Bacci V, Pollin TI, Poehlman ET, Shuldiner AR, Celi FS. Association between a novel variant of the human type 2 deiodinase gene Thr92Ala and insulin resistance: evidence of interaction with the Trp64Arg variant of the beta-3-adrenergic receptor. Diabetes 2002; 51: 880-3.
17. Panicker V, Cluett C, Shields B, Murray A, Parnell KS, Perry JR, Weedon MN, Singleton A, Hernandez D, Evans J, Durant C, Ferrucci L, Melzer D, Saravanan P, Visser TJ, Ceresini G, Hattersley AT, Vaidya B, Dayan CM, Frayling TM. A common variation in deiodinase 1 gene DIO1 is associated with the relative levels of free thyroxine and triiodothyronine. J Clin Endocrinol Metab 2008; 93: 3075-81.
18. Hoftijzer HC, Heemstra KA, Visser TJ, le Cessie S, Peeters RP, Corssmit EP, Smit JW. The type 2 deiodinase ORFa-Gly3Asp polymorphism (rs12885300) influences the set point of the hypothalamus-pituitary-thyroid axis in patients treated for differentiated thyroid carcinoma. J Clin Endocrinol Metab 2011; 96: E1527-33.
19. Torlontano M, Durante C, Torrente I, Crocetti U, Augello G, Ronga G, Montesano T, Travascio L, Verrienti A, Bruno R, Santini S, D'Arcangelo P, Dallapiccola B, Filetti S, Trischitta V. Type 2 deiodinase polymorphism (threonine 92 alanine) predicts L-thyroxine dose to achieve target thyrotropin levels in thyroidectomized patients. J Clin Endocrinol Metab 2008; 93: 910-3.
20. Heemstra KA, Hoftijzer HC, van der Deure WM, Peeters RP, Fliers E, Appelhof BC, Wiersinga WM, Corssmit EP, Visser TJ, Smit JW. Thr92Ala polymorphism in the type 2 deiodinase is not associated with T4 dose in athyroid patients or patients with Hashimoto thyroiditis. Clin Endocrinol (Oxf) 2009; 71: 279-83.
21. Tuttle RM, Leboeuf R, Shaha AR. Medical management of thyroid cancer: a risk adapted approach. J Surg Oncol 2008; 97: 712-6.
22. CubeX: Cubic Exact Solution. Available at http://www.oege.org/software/cubex/(last accessed 10 February 2014).
23. Haplo-stats softaware. Available at http://www.mayo.edu/research/labs/statistical-genetics-genetic-epidemiology/software (last accessed 10 February 2014).
24. Instituto Brasileiro de Geografia e Estatística. Available at http://www.sidra.ibge.gov.br/bda/tabela/listabl.asp?z =t&c=262 (last accessed 10 February 2014).
25. Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med 1982; 96: 53-5.
26. Cunningham JJ, Barzel US. Lean body mass is a predictor of the daily requirement for thyroid hormone in older men and women. J Am Geriatr Soc 1984; 32: 204-7.
27. Sawin CT, Herman T, Molitch ME, London MH, Kramer SM. Aging and the thyroid. Decreased requirement for thyroid hormone in older hypothyroid patients. Am J Med 1983; 75: 206-9.
28. Santini F, Pinchera A, Marsili A, Ceccarini G, Castagna MG, Valeriano R, Giannetti M, Taddei D, Centoni R, Scartabelli G, Rago T, Mammoli C, Elisei R, Vitti P. Lean body mass is a major determinant of levothyroxine dosage in the treatment of thyroid diseases. J Clin Endocrinol Metab 2005; 90: 124-7.
29. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics 2006; 7: 1211-21.
30. Peeters RP, van Toor H, Klootwijk W, de Rijke YB, Kuiper GG, Uitterlinden AG, Visser TJ. Polymorphisms in thyroid hormone pathway genes are associated with plasma TSH and iodothyronine levels in healthy subjects. J Clin Endocrinol Metab 2003; 88: 2880-8.
31. van der Deure WM, Hansen PS, Peeters RP, Uitterlinden AG, Fenger M, Kyvik KO, Hegedüs L, Visser TJ. The effect of genetic variation in the type 1 deiodinase gene on the interindividual variation in serum thyroid hormone levels: an investigation in healthy Danish twins. Clin Endocrinol (Oxf) 2009; 70: 954-60.
32. Gereben B, Kollár A, Harney JW, Larsen PR. The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression. Mol Endocrinol 2002; 16: 1667-9.
33. Coppotelli G, Summers A, Chidakel A, Ross JM, Celi FS. Functional characterization of the 258 A/G (D2-ORFa-Gly3Asp) human type-2 deiodinase polymorphism: a naturally occurring variant increases the enzymatic activity by removing a putative repressor site in the 5? UTR of the gene. Thyrs Soid 2006; 16: 625-6.